Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- Generic Picks Will Depend on Regions as Joint Purchase Gets Underway, Iwasaki Says on Teva JV
February 22, 2017
- Debiopharm Takes Nippon Kayaku to Supreme Court over Elplat
February 22, 2017
- With Positive PIII Data, AZ Aims for Olaparib’s Japan Approval in 2018
February 22, 2017
- Chugai/Roche’s Alecensa Approved in Europe
February 22, 2017
- Takeda’s Consumer Healthcare Biz Split-Off Going as Scheduled
February 21, 2017
- In Yet Another Setback, Daiichi Sankyo’s Tivantinib Fails Liver Cancer PIII
February 21, 2017
- Rexulti Approved in Canada: Otsuka
February 21, 2017
- Takeda’s Cx601 Stem Cell Therapy Shows Long-Term Effect
February 21, 2017
- Entyvio Delivers 95%-Plus Clinical Response for UC, CD at 5 Years
February 21, 2017
- Look at Value-Based Price Gap, Not Percentages, Sawai Says on Partial Revisions
February 20, 2017
- EA Pharma President Shimizu Dies at 59
February 20, 2017
- Takeda’s Ariad Acquisition Completed
February 20, 2017
- Chugai Files PD-L1 Inhibitor Atezolizumab in Japan
February 20, 2017
- Osaka Univ. Inks Another 10-Year Immunology Pact, This Time with Otsuka
February 17, 2017
- Eisai Gets Rights for 2 Orion Parkinson’s Meds in China
February 17, 2017
- Takecab Most Heavily Promoted Drug in HP Market in December: Anterio
February 16, 2017
- Takeda, PRA to Launch JV in Japan to Take Over 140 Employees
February 16, 2017
- Ono Looks for New Growth through Opdivo Despite NHI Price Cut: President
February 16, 2017
- Bristol-Myers Looks to Crack into Genotype 1 Hep C Market as Ximency Clears Resistance Mutation Hurdle
February 15, 2017
- Keytruda Now Available in Japan
February 15, 2017
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…